SDGR Schrodinger, Inc.

BUSINESS SUMMARY

Schrödinger sells physics-based molecular-simulation software to pharmaceutical and biotech companies for use in drug discovery — predicting how candidate molecules will bind to disease targets, optimizing molecular structures for drug-like properties, and prioritizing which compounds to synthesize and test in the wet lab. The platform combines decades of computational-chemistry research with modern machine-learning approaches.

The customer base spans the major pharmaceutical companies plus most well-funded biotech startups, making Schrödinger one of the few software companies with deep penetration across both ends of the drug-discovery industry. Revenue is subscription licensing for the software platform plus collaboration-and-milestone revenue from drug-discovery partnerships where Schrödinger participates economically in compound advancement.

The strategic ambiguity is the proprietary-pipeline strategy: Schrödinger uses its own platform to develop internal drug candidates that the company is now advancing in partnership with major pharma (Bristol-Myers Squibb's collaboration on multiple programs being the most prominent), creating equity-stake economics in addition to software-licensing revenue.

MARKET OPPORTUNITY

The drug-discovery software market sits at the intersection of two structural growth themes:

• AI-and-computational drug discovery is one of the most-funded biotech-adjacent investment categories
• Pharma R&D productivity pressure drives major pharmaceutical companies to seek computational-platform tools that reduce wet-lab cost-and-cycle-time

Schrödinger's positioning is technically defensible — the physics-based-plus-ML approach has been validated through multi-year partnerships with major pharma. The challenge is that competing platforms (Atomwise, Recursion, Insitro, plus internal teams at every major pharma) are well-funded and the eventual market-structure is uncertain.

Revenue growth varies by quarter depending on milestone-and-collaboration timing in addition to underlying subscription-licensing growth.

REVENUE QUALITY

• Gross margin 62% — moderate-to-high; reflects both software-licensing economics and the lower-margin services-revenue mix
• Operating margin — TTM negative; ongoing R&D investment in proprietary pipeline and platform-development dominates
• Revenue ~$215M TTM
• P/S ~5 — premium reflecting AI-thematic-investor demand plus pipeline-NPV optionality

The right analytical framework: subscription-software ARR growth as the through-cycle metric, with milestone-and-collaboration revenue treated as lumpy supplementary income. Standard P/S obscures the layered economics.

COMPETITIVE ADVANTAGE

Schrödinger's defensible asset is the multi-decade physics-based simulation IP combined with the customer-relationship depth at major pharma:

• Free-energy-perturbation accuracy — Schrödinger's FEP+ has been the benchmark for binding-affinity prediction in computational chemistry for years
• Multi-decade customer relationships that compound feedback into platform improvements
• Proprietary-pipeline dual-positioning — the company isn't just selling software, it's using the software to develop drugs alongside customers, providing both market-credibility and equity-upside

Direct competitors include OpenEye Scientific (Cadence-acquired), Cresset, Optibrium, plus newer ML-focused platforms (Atomwise, Recursion). None directly replicates the physics-plus-ML positioning at Schrödinger's scale of customer adoption.

GROWTH THESIS

Three structural drivers support multi-year growth:

1. Subscription-platform ARR continues compounding as more biotech and pharma customers adopt computational-discovery workflows
2. Proprietary-pipeline programs advance — successful clinical readouts on Schrödinger-and-partner-developed compounds validate the platform and provide milestone revenue
3. Platform-feature expansion — expanding from small-molecule discovery into biologics, peptides, and other modalities

The wildcard is Bristol-Myers Squibb collaboration economics — the multi-target partnership has milestone payments that depend on clinical advancement of multiple programs. Successful program advancement provides both immediate milestone revenue and validates the platform broadly.

KEY RISKS

The risks cluster around platform-competitive-validation and proprietary-pipeline-execution. Computational-discovery as a category is well-funded; any meaningful clinical-validation failure across the broader category (a high-profile clinical failure of an AI-discovered compound, for instance) compresses the entire thematic. Schrödinger-specific: continued R&D-investment requirement keeps operating margin pressured, and the proprietary-pipeline programs carry all the binary clinical-trial risk of any drug-development effort.

VERDICT

Schrödinger is the most-credible public-market computational-drug-discovery platform — multi-decade physics-based IP combined with extensive customer adoption at major pharma. The 62.3/100 score captures fundamental quality but the platform-and-pipeline dual-economics are imperfectly captured by conventional fundamental screening.

For investors who want exposure to AI-and-computational drug-discovery as a long-duration thematic with both software-licensing economics and proprietary-pipeline optionality, SDGR is one of few liquid public-market vehicles. For investors needing pure-software economics or wanting to avoid clinical-trial-risk exposure embedded in the proprietary-pipeline business, the dual-positioning is the wrong vehicle.